ProKidney Stock Soars 33.78% on Positive Trial Data

On July 9, 2025, ProKidney's stock price surged by 33.78% in pre-market trading, driven by the release of promising mid-stage trial data for its lead drug, Rilparencel, in the treatment of chronic kidney disease.

ProKidney's shares soared following the announcement of positive results from its Phase 2 REGEN-007 trial. The trial data showed statistically significant improvements in kidney function, which has bolstered confidence in the ongoing Phase 3 PROACT 1 trial. The company plans to submit the full REGEN-007 data for presentation at the 2025 ASN Kidney Week and is preparing for an upcoming FDA Type B meeting regarding accelerated approval pathways.

Analysts have responded positively to the trial results, with Citi raising its price target on ProKidney to $9.00 from $6.00 while maintaining a Buy rating. The market's enthusiasm for the results was evident as ProKidney's stock closed significantly higher, reflecting investor optimism about the potential of Rilparencel as a treatment for chronic kidney disease.